Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.8725 -0.0241 (-2.69%)
Streaming Delayed Price Updated: 2:09 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amarin Corp ADR

< Previous 1 2 3 4 5 6 Next >
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards
From Sarissa Capital Management LP
Via Business Wire
Amarin Shareholders Invited to Webcast with Board and Management Team
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Does Not Believe Amarin Cares About Shareholders
From Sarissa Capital Management LP
Via Business Wire
Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Highlights Amarin’s Inaccurate and Misleading Statements
From Sarissa Capital Management LP
Via Business Wire
Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts
Company Files Investor Presentation and Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card 
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Highlights Amarin’s Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin
From Sarissa Capital Management LP
Via Business Wire
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at SVB Securities Global Biopharma Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Calls Out Amarin’s Sham Board Refreshment
From Sarissa Capital Management LP
Via Business Wire
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management 
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen
From Sarissa Capital Management LP
Via Business Wire
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at Jefferies London Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Issues Statement in Response to Sarissa
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members
From Sarissa Capital Management LP
Via Business Wire
3 Biotech Stocks Gaining Momentum
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power. 
Via MarketBeat
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.